Last updated 2026-07-20
- Went public on NASDAQ (URGN), May 2017
- Raised $18M Series B led by Two River, Oct 2015
- Raised $7M Series A led by Pontifax, Apr 2013
Total raised
$26.5M
Last: Debt Financing 2026-02
Stage
Public
Founded
2004
Headcount
298
HQ
Ra'anana, Israel
Sector
Health Tech & Life Sciences
About
UroGen Pharma is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company utilizes its proprietary RTGel reverse-thermal hydrogel technology, a sustained-release, hydrogel-based platform, to improve the therapeutic profiles of existing drugs. This technology is designed to enable longer exposure of urinary tract tissue to medications, offering a potentially more effective local treatment option. UroGen's product pipeline includes treatments for low-grade upper tract urothelial cancer (UTUC) and non-muscle invasive bladder cancer (NMIBC).
Funding history · 15 rounds · $26.5M total
2026-03
Debt Financing
Undisclosed
2025-02
PIPE
Undisclosed
2024-09
Debt Financing
Undisclosed
2024-06
Follow-on PO
Undisclosed
2023-07
PIPE
Undisclosed
2022-12
Follow-on PO
Undisclosed
2022-10
Debt Financing
Undisclosed
2022-03
Debt Financing
Undisclosed
2020-01
Follow-on PO
Undisclosed
2019-01
Follow-on PO
Undisclosed
2018-01
Follow-on PO
Undisclosed
2017-05
IPO
Undisclosed
2015-10
B Round
$18.0M
★ Two River
2013-04
A Round
$7.0M
★ Pontifax
2009-12
Seed
$1.5M
★ Pontifax
Headcount over time
From 50 (2019-02) to 319 (2026-03) · +269 (+538%) · 24 points · source: Finder history + radar grounding
Q&A
- What was UroGen Pharma's most recent funding round?
- UroGen Pharma completed a Debt Financing round in February 2026, raising $250,000,000 from Pharmakon Advisors.
- When did UroGen Pharma last conduct a public offering?
- UroGen Pharma had a Public Offering in June 2024, raising $107,500,000.
- What is UroGen Pharma's primary focus in terms of therapies?
- UroGen Pharma focuses on urologic oncology therapies, developing novel solutions for specialty cancers and urologic diseases.
- What is RTGel?
- RTGel is UroGen Pharma's proprietary sustained-release, hydrogel-based platform technology designed to improve the therapeutic profiles of existing drugs by enabling longer exposure of urinary tract tissue to medications.
- What are UroGen Pharma's lead product candidates?
- UroGen Pharma's lead product candidates are UGN-101 (mitomycin urothelial gel, known as MitoGel) and UGN-102 (mitomycin intravesical gel, known as VesiGel), which are designed for non-surgical tumor removal and treatment of non-muscle-invasive urothelial cancer.
- When was UroGen Pharma founded?
- UroGen Pharma was founded in April 2004.
- What is the current employee count for UroGen Pharma?
- UroGen Pharma has 201-500 employees.
- What is UroGen Pharma's current market capitalization?
- UroGen Pharma has a market capitalization of $1,096,264,251.
Team · 1
Asher Holzer
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDrug Delivery
Technologies
BiologicalsCells
Target customers
ConsumersDemographics & FamilyMenHealthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
oncologydrug-deliverysustained-releaseurologypharmaceuticalsorphan-drugnon-surgicalpharma-companiesdrug-designcancer
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | urogen.com |
|---|---|
| linkedin.com/company/11520884 | |
| YouTube | youtube.com/channel/UCfocvR6Si3Awb5beahHHlzg |
| Wikidata | wikidata.org/wiki/Q140045834 |
Identifiers & details
| Legal name | UroGen Pharma Ltd. |
|---|---|
| Former names | Theracoat, TheraCoat |
| Founded | 2004-4 |
| Employees (exact) | 298 |
| Offices | Princeton |
| Market cap | $1.1B |
| Status reason | Public on NASDAQ on May 2017; |
| Wikidata QID | Q140045834 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2017-05 | NASDAQ | URGN | $66.9M |
| Public Offering | 2018-01 | NASDAQ | URGN | $60.0M |
| Public Offering | 2024-06 | NASDAQ | URGN | $107.5M |
Radar intelligence
Patents
| EPO | 24 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
Web history (Wayback)
| Domain | urogen.com |
|---|
Wikidata
| QID | Q140045834 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513537621 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2004-04-28 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2022 |
| Active charges / liens | 0 |
| Registry events | 6 — charge (5), people (1) |
| Registered address | התעשיה 9 רעננה |
Recent registry events
| Date | Event |
|---|---|
| 2026-02-11 | סילוק שעבוד |
| 2026-02-11 | סילוק שעבוד |
| 2026-02-11 | סילוק שעבוד |
| 2026-03-09 | עדכון בעלי תפקידים |
| 2026-03-05 | רישום שעבוד |
| 2026-03-05 | רישום שעבוד |